J.P. Morgan analyst Jessica Fye maintains $Vertex Pharmaceuticals (VRTX.US)$ with a buy rating, and sets the target price at $503.
According to TipRanks data, the analyst has a success rate of 52.0% and a total average return of 6.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Vertex Pharmaceuticals (VRTX.US)$'s main analysts recently are as follows:
Vertex Pharmaceuticals' Q3 results exceeded consensus expectations, and the company increased its 2024 revenue guidance slightly, by approximately 1% at the midpoint. The forthcoming suzetrigine Phase 2 lumbosacral radiculopathy (LSR) data, anticipated by the end of the year, is expected to be the next significant event for the company's stock.
The company's robust performance in cystic fibrosis, which surpassed expectations and led to a raised forecast, demonstrates the ongoing strength of its fundamental business. This is expected to continue supporting the stock's premium valuation. However, there are cautions that the outlook heading into FY25 may present more challenges compared to FY24, considering that upcoming data for suzetregine is anticipated to meet effectiveness criteria but may not generate significant enthusiasm, and the introductions of acute pain treatments and Casgevy are expected to experience gradual market penetration.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
摩根大通分析師Jessica Fye維持$福泰製藥 (VRTX.US)$買入評級，目標價503美元。
根據TipRanks數據顯示，該分析師近一年總勝率為52.0%，總平均回報率為6.3%。
此外，綜合報道，$福泰製藥 (VRTX.US)$近期主要分析師觀點如下：
福泰製藥第三季度業績超出共識預期，公司稍微增加了2024年的營業收入預測，中間值增加約1%。預計將於年底公佈的suzetrigine Phase 2腰神經痛（LSR）數據，預計將成爲公司股票的下一個重要事件。
公司在囊性纖維化領域的強勁表現超出預期，並帶來了預測的提高，展示了其基本業務持續的實力。預計這將繼續支撐股票的溢價估值。然而，有人士對於FY25的展望提出了警告，可能會比FY24面臨更多挑戰，考慮到即將公佈的suzetregine數據預計將符合有效性標準，但可能不會引起重大熱情，急性疼痛治療和Casgevy的推出預計將經歷逐漸的市場滲透。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
